

Meeting of the *NCEL* Cancer Alliance Urology Cancer Pathway Board meeting

Date: **Thursday 12th September 2019, 16:30-18:00**

Venue: **Boardroom, UCLH @ Westmoreland Street, London, W1G 8PH**

Chair: **John Hines**

1. Welcome and introductions and Minutes from last meeting

- John Hines welcomed the group.
- The minutes of the last meeting were accepted as an accurate record of proceedings.

Actions

- APR18-01. Costi Alifrangis is currently updating the prostate chemotherapy guidelines which will be signed off at the next pathway board meeting
- FEB19-01. Action complete
- MAY19-01 – It has been agreed that the network would continue to use the current post-RALP pathway that is to be shared with the pathway board. John Sandell highlighted that, from a patient's perspective it is beneficial to be followed up at your local hospital as soon as possible. John Hines stated that this action was in response to concerns raised by Whittington regarding how patients are followed up following their RALP. It is important that all patients seen at UCLH follow the same pathway and John Hines has spoken to Geoff Bellingan who will be liaising with Whittington in regards to these concerns.
- MAY19-04 – John Hines to discuss with Kate Rees.

2. Cancer Alliance – Future Plans for Pathway Boards

- Naser Turabi, Programme Director for the North Central and East London Cancer Alliance updated the board on the changes to the cancer alliance governance structure.
- The purpose of the cancer alliance and tumour pathway boards has developed over the past couple of from their original establishment under London Cancer and then as part of the National Cancer Vanguard. In 2017 cancer alliances were established in every region within England, the purpose of these cancer alliances is to provide system leadership; reducing unwarranted variation in practice and ensuring organisations within the sector work together to deliver services that cannot be delivered on their own. This is different from the original purpose of London Cancer, that focussed on reconfiguration and the National Cancer Vanguard that focussed on innovation.

UCLH Cancer Collaborative brings together hospital trusts, GPs, health service commissioners, local authorities and patients across north and east London and west Essex.

Prof Kathy Pritchard-Jones – Chief Medical Officer

Naser Turabi – Programme Director

Email uclh.cancercollaborative@nhs.net

Address 47 Wimpole Street, London W1G 8SE

Website www.uclh.nhs.uk/cancercollaborative

Read our blog at www.uclh.nhs.uk/cancerblog

- NHSE London, in 2018 asked Sir Mike Richards to undertake a governance review of the NCEL Cancer Alliance due to the network not being able to meet the 62 day performance target. The review focussed on how the NCEL cancer alliance should evolve to meet its new purpose.
- During the review Mike Richards interviewed colleagues across the cancer alliance in both primary and secondary care and his final recommendation was that the cancer alliance should separate to align with the STPs within the network. This would mean one cancer alliance in NCL and one in NEL.
- The report provided two main reasons for this recommendation:
 1. As the cancer alliance evolves its purpose to providing system leadership it would benefit from aligning its governance structures with the STPs.
 2. Aligning the cancer alliance with the two STPs will enable it to support its full remit of earlier diagnosis, rapid diagnosis and treatment and to support patients living with and beyond cancer.
- It was agreed that the network would accept this recommendation and form two separate alliances from April 2020.
- This year we are focussing on developing the governance structures for the two new cancer alliances. In July 2019 an external consultancy company developed, alongside the cancer alliance design group draft design principles that were presented to the cancer alliance board.
- Naser Turabi presented this to the board which include the proposed principles for how pathway boards and expert reference groups should function within the new cancer alliance governance structures.
- Currently Prof Muntzer Mughal is leading a review of the pathway boards and expert reference groups to determine how they are best configured under the new governance structure; this includes a discussion with the pathway board about how they feel the board should continue from April 2020.
- Naser Turabi highlighted that specialised commissioning have requested that strong working relationships continue across the two alliances in tumour sites where patient pathways flow across STP boundaries. It is therefore envisaged that for pathway boards such as Urology one pathway board will remain supporting the two new cancer alliances.
- John Hines highlighted that when London Cancer sat under UCLP, pathway board directors had an opportunity to discuss and meet with senior executive leadership within trusts which no longer exists. Naser Turabi confirmed that, under the new governance structures pathway boards will be supported by the Cancer Alliance Board that will be attended by trust CEOs.
- Anand Kelkar emphasised the importance of the pathway board being supported by the cancer alliance to ensure that decisions being made are then carried out within trusts.
- The board agreed that the pathway board should remain across the two cancer alliances with representatives from North Central and East London. The board also agreed that it should remain as the urology pathway board and should not be divided into separate tumour groups.

<p>ACTION: JG to complete feedback template and disseminate to board before being submitted to the Pathway Board Review.</p>

3. MDT Streamlining

- Sophie Morris updated the board on the NCEL Cancer Alliance MDT Streamlining programme.
- The BHRUT MDT is already working with the cancer alliance to develop protocols to support the streamlining of the urology sMDT.
- Sophie Morris highlighted that national guidance on MDT streamlining is due to be published soon however the cancer alliance has £15,000 to support a development group to define the protocols that can be used to streamline the MDT/sMDT.

- John Hines highlighted that UCLH has already begun to pilot some protocols within their sMDT.
- John Hines suggested that Sophie Morris should attend the next Urology sMDT meeting to discuss this with the sMDT leads in more detail.

ACTION: sMDT leads meeting to be arranged to discuss MDT streamlining.

4. Stratified Follow Up

- Sarita Yaganti updated the board on the work currently being carried out in regards to stratified follow up for prostate cancer patients.
- A meeting has been arranged on 5th November to discuss the stratified follow up pathway in North Central London. Invitations have been sent to all trusts within NCL for this meeting.
- The aim of this meeting is to develop an action plan on how best to deliver the stratified follow up pathway and will be attended by both clinicians and operational managers.
- Veronica Brinton highlighted the importance of ensuring that patient information is clear and simple so that they understand the process of being followed up in primary care. Jane Smith emphasised the importance of a structured process to ensure that patients receive an appointment with their GP following discharge from the hospital.
- Sarita Yaganti reassured the board that several safety nets have been put in place within the pathway to ensure patients are not lost in the system.
- Hilary Baker stated that the forms needed to be filled out to discharge a patient onto a stratified follow up pathway are labour intensive and that this process should be streamlined.
- Representatives from North East London updated that they are now almost in a position to start their stratified follow up pathways.

5. Guidelines for the Diagnosis of Prostate Cancer

- The board ratified the updated prostate diagnostic guidelines which were updated following the Prostate Biopsy Consensus Meeting on 5th June 2019.

6. AOB

- Paras Singh highlighted that PSMA PET has now been commissioned by NHS England. The board agreed that PSMA should continue to be used.

Next meeting date: 21st November, 16:30-18:00

ACTION LOG

Action Reference	Action	Owner	Date Due	Status
APR18-01	Prostate chemotherapy guidelines to be established	Costi Alifrangis/John Hines	21/11/2019	
FEB 19-01	Quality of life to be included on next meeting's agenda.	Jacob Goodman	12/09/2019	complete
MAY19-01	JH/HB to write up the post-RALP pathway including necessary communication points	John Hines/Hilary Baker	01/10/2019	
MAY19-03	Gateway 6 for renal cancer to be taken to the appropriate governance forum for approval.	Axel Bex	12/09/2019	Complete
MAY19-04	JH to write to Kate Rees regarding referrals for other conditions following a PSA.	John Hines	30/06/2019	
SEP19-01	JG to complete feedback template and disseminate to board before being submitted to the Pathway Board Review.	Jacob Goodman	10/10/2019	complete
SEP19-02	sMDT leads meeting to be arranged to discuss MDT streamlining.	Sophie Morris	01/11/2019	complete

Attendees

Name	Role	Trust/Organization
John Hines	Pathway Board Director	NCEL Cancer Alliance
Jacob Goodman	Senior Project Manager	NCEL Cancer Alliance
Paras Singh	Consultant Urologist	Royal Free
Sarita Yaganti	Macmillan Stratified Pathways Lead	NCEL Cancer Alliance
Jane Smith	Patient Representative	
Rosie Batty	General Manager	UCLH
Reena Davda	Consultant Oncologist	UCLH
Ashwin Sridhar	Consultant Urologist	UCLH
Sophie Morris	Senior Project Manager	NCEL Cancer Alliance
Hilary Baker	CNS	UCLH
Anne Carey	Deputy Chief Operating Officer	Princess Alexandra
Nikita Silhi	GP	Enfield CCG
John Sandell	Patient Representative	
Veronica Brinton	Patient Representative	
Naser Turabi	Programme Director	NCEL Cancer Alliance
Sharon Cavanagh	Programme Lead	NCEL Cancer Alliance
Hussain Alnajjar	Consultant Urologist	UCLH
Anand Kelkar	Consultant Urologist	BHRUT

Apologies

Name	Role	Trust/Organization
Mark Feneley	Consultant Urologist	UCLH
Gillian Smith	Clinical Director	Royal Free
Stefanos Almpanis	Consultant Urologist	North Middlesex
Victoria Wood	Respect-21	UCL
Caroline Moore	Consultant Urologist	UCLH
Axel Bex	Consultant Urologist	Royal Free
Karen Tipples	Consultant Oncologist	Barts Health
Tom Powles	Consultant Oncologist	Barts Health
Ashoke Roy	Consultant Urologist	Royal Free
Sandeep Pathak	Consultant Radiologist	Barts Health
Jeevan Kumaradevan	Consultant Radiologist	Whittington
Waseem Akhter	Consultant Urologist	Princess Alexandra
Frank Chinegwundoh	Consultant Urologist	Barts Health
Heather Payne	Consultant Oncologist	UCLH